Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...
Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...
Panome Bio, a CRO, launched MassID™, a cloud-based computational platform designed to improve how researchers process and interpret untargeted LC/MS metabolomics data. The platform is described in a ...
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other related disorders, represent a ...
ROCKVILLE, Md.--(BUSINESS WIRE)--BrainScope, a leader in brain diagnostics, today announced the successful completion of the proof-of-concept phase for a novel brain activity-based biomarker for the ...
The world is currently undergoing a significant transformation in biomarker science. Biomarker signatures are no longer academic luxury or exploratory afterthoughts; they have matured into strategic ...
Hello, and welcome to Herantis Pharma's Phase Ib Biomarker Data webinar. I am CEO, Antti Vuolanto, joined today by CSO, Henri Huttunen; and CFO, Tone Kvale. We are really excited to discuss yesterday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results